Zai Lab Ltd.
http://www.zailaboratory.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zai Lab Ltd.
China In-Licensing Crossroads: Zai Lab, Everest March Towards Market But BioNova Returns Rights
China's Zai Lab and Everest are still pursuing profitability on the commercialization of in-licensed assets, while BioNova and others have already bowed out of the game.
As Vyvgart Surges To Blockbuster Status, Argenx Maps Out Expansion Plans
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.
Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
LianBio Eyes ‘Strategic Review’ As It Hands Camzyos Asia Rights Back To MyoKardia Parent BMS
BMS, which acquired MyoKardia in 2020 months after LianBio acquired rights in certain Asia-Pacific territories, said the deal would help expand its footprint in China.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Zai Lab Limited
- Zai Lab (Shanghai) Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice